术后辅助化疗在结肠癌的临床应用及安全性分析

目的探讨Ⅲ期结肠癌患者根治术后行辅助化疗的临床疗效及安全性。方法回顾性分析110例Ⅲ期行结肠癌根治术患者的临床资料,其中术后行辅助化疗者62例,单纯手术者48例。比较两组患者3年复发转移率、无病生存时间及辅助化疗组的不良反应。结果辅助化疗组3年复发转移率显著低于对照组（24.2%vs 35.4%）,差异有统计学意义（P〈0.05）;辅助化疗组与单纯手术组无病生存时间分别为18个月和12个月,两组比较,差异有统计学意义（P〈0.05）。食欲不振、恶心呕吐、脱发及色素沉着为辅助化疗组最常见的不良反应,但患者大都可耐受。结论Ⅲ期结肠癌患者根治术后行辅助化疗可显著提高患者无病生存时间,不良反应大都可耐受。

Clinical application and safety analysis of post-operation adjuvant chemotherapy in colorectal carcinoma

Objective To explore the clinical application and safety of post-operation adjuvant chemotherapy in the patients with colorectal carcinoma undergoing radical resection surgery.Methods Clinical data of 110 patients with stage Ⅲ colorectal carcinoma undergoing radical resection surgery were retrospectively analyzed.110 patients were divided into adjuvant chemotherapy group(62 cases) and single operation group(48 cases).3-year recurrence rate,disease-free survival time and adverse reactions of the two groups were analyzed.Results 3-year recurrence rate of adjuvant chemotherapy group was lower than that of single operation group(24.2% vs 35.4%),there was a significant difference(P<0.05).Diseasefree survival time in adjuvant chemotherapy group and single operation group was 18 months and 12 months respectively, there was a significant difference(P<0.05).Anorexia,nausea/vomiting,alopecie and pigmentation were the main adverse reactions in adjuvant chemotherapy group.Most of the adverse reactions were tolerable for the patients.Conclusion Stage Ⅲ colorectal carcinoma undergoing radical resection surgery can greatly improve disease-free survival time of the patients, the patients can endure most of adverse reactions.